Loading...
01/10 16:41
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed strong financial performance, with a 53% YoY revenue increase and solid adjusted EBITDA growth. The acquisition of CHS and Prospect Health is expected to drive future revenue and EBITDA growth. The Q&A highlighted successful integration efforts and confidence in Prospect's earnings power. Despite some uncertainties in Medicaid trends and rate assumptions, overall guidance remains optimistic. The company's strategic focus on membership growth and value-based contracts supports a positive outlook, likely leading to a 2%-8% stock price increase over the next two weeks.
Total Revenue $620.4 million, a 53% increase year-over-year driven by strong organic growth in core business and acquisitions of CFC and CHS.
Adjusted EBITDA $36.4 million, reflecting growth in membership and value-based arrangements while managing costs effectively.
Net Income $6.7 million, with EPS of $0.14 per share.
Cash and Short-term Investments $260.9 million at the end of the quarter.
Free Cash Flow $13.6 million, including a non-recurring debt issuance cost of $5 million; excluding this cost, free cash flow was $18.6 million, representing 51% of adjusted EBITDA.
Membership in Care Partners Segment 910,000 members, with 38% in full risk contracts, up from 5.5% a year ago.
Capitated Revenue from Full Risk Members 75% of capitated revenue now comes from full risk members.
Medical Cost Trend In line with expectations in the mid-single-digits, with Medicaid trend above and Medicare and commercial trend below that blended average.
Pro Forma Net Leverage Expected to be approximately 3.4 times post-acquisition of Prospect Health.
Membership Growth: Our Care Partners segment continues to expand reaching 910,000 members as of Q1, 2025.
Full Risk Contracts: Approximately 38% of our members are now in full risk contracts, up from 5.5% a year ago.
Nevada Market Growth: Membership in our risk-bearing network grew 40% and clinic visit volume increased by 35% year-over-year in Nevada.
Texas Market Progress: We remain on track with reaching profitability in Texas by late-2025.
Prospect Health Acquisition: The acquisition will significantly expand our provider network in Southern California, serving approximately 1.7 million members.
Revenue Growth: Astrana generated total revenue of $620.4 million, a 53% increase compared to the prior year period.
Adjusted EBITDA: Delivered adjusted EBITDA of $36.4 million.
G&A Efficiencies from CHS: Identified and executed on over $10 million in G&A efficiencies as CHS has onboarded to our proprietary technology platform.
Free Cash Flow: Generated $13.6 million in free cash flow, or $18.6 million excluding non-recurring costs.
Acquisition Strategy: In 2025, our priority shifts to executing on growth to unlock greater value across the platform.
Leadership Additions: New leadership includes Chief Data and Analytics Officer and Chief Accounting Officer to support growth and scalability.
Medicare Advantage Rates: Encouraged by the 2026 Medicare Advantage rate notice, signaling continued federal support for value-based care.
Forward-Looking Statements: The company acknowledges that its forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from projections.
Regulatory Issues: California's Proposition 35 is being monitored for its implications, but the current view is that the net impact will be neutral to EBITDA once resolved.
Medicare Advantage Rates: While the 2026 Medicare Advantage rate notice is seen as a positive signal, any changes in federal support could impact future business.
Acquisition Risks: The integration of CHS and the planned acquisition of Prospect Health carry risks related to execution and realization of expected synergies.
Economic Factors: The company operates in a challenging economic environment, which could affect growth and profitability.
Supply Chain Challenges: There are potential challenges related to supply chain management, particularly in the context of healthcare delivery and operational execution.
Market Competition: Competitive pressures in the healthcare market could impact Astrana's growth and market share.
Risk Exposure: The company has limited exposure to Part D risk, which is a strategic decision to avoid areas where control is limited.
Strategic Pillars: Astrana's strategy is built on four pillars: sustainably growing membership, aligning patient outcomes with financial performance, improving care quality while managing costs, and driving operational excellence through a proprietary Care Enablement platform.
Acquisition Strategy: The company is focused on executing growth from previous acquisitions, particularly CHS, which is expected to reach breakeven profitability in 2025 and profitability in 2026.
Leadership Additions: New leadership appointments include Chief Data and Analytics Officer, Chief Accounting Officer, and Chief People Officer to strengthen the organization.
Market Expansion: Astrana is expanding its presence in Nevada and Texas, with Nevada achieving breakeven in Q1 and Texas on track for profitability in late 2025.
Technology Integration: Integration of CHS onto Astrana's platform has been completed, identifying over $10 million in G&A efficiencies.
2025 Revenue Guidance: Astrana expects full year revenue between $2.5 billion to $2.7 billion.
2025 Adjusted EBITDA Guidance: Adjusted EBITDA is projected to be between $170 million to $190 million for the full year.
Q2 2025 Revenue Guidance: For Q2 2025, revenue is expected to be between $615 million to $665 million.
Q2 2025 Adjusted EBITDA Guidance: Adjusted EBITDA for Q2 2025 is expected to range between $45 million to $50 million.
Medium-term EBITDA Guidance: Medium-term adjusted EBITDA guidance is at least $350 million by 2027.
Free Cash Flow: $13.6 million generated in Q1 2025, with $18.6 million excluding non-recurring costs.
Acquisition of Prospect Health: Expected to contribute around $81 million in adjusted EBITDA and deliver between $12 million to $15 million in synergies.
Net Income: $6.7 million for Q1 2025.
Earnings Per Share (EPS): $0.14 per share.
Revenue Guidance: Full year guidance of $2.5 billion to $2.7 billion.
Adjusted EBITDA Guidance: Full year guidance of $170 million to $190 million.
Medium-term Adjusted EBITDA Guidance: At least $350 million in 2027.
The earnings call indicates positive sentiment with strong revenue guidance for 2025, optimistic medium-term EBITDA projections, and a strategic partnership with Intermountain Health. Despite a minor EBITDA reduction due to timing delays, the company's focus on deleveraging and synergy savings, along with stable cash flow and improving Medicaid trends, are favorable. The Q&A section did not reveal significant negative concerns, and the partnership and revenue growth are expected to positively impact the stock price.
The earnings call presents mixed signals. While there are positive aspects like market expansion, breakeven achievements, and optimistic guidance, there are significant concerns such as potential revenue headwinds from Medicaid changes and lack of clarity in management's responses. The company's conservative approach in its guidance and the impact of legislative changes in California also add uncertainty. These factors, combined with the absence of a market cap, suggest a neutral stock price movement in the short term.
The earnings call revealed strong financial performance, with a 53% YoY revenue increase and solid adjusted EBITDA growth. The acquisition of CHS and Prospect Health is expected to drive future revenue and EBITDA growth. The Q&A highlighted successful integration efforts and confidence in Prospect's earnings power. Despite some uncertainties in Medicaid trends and rate assumptions, overall guidance remains optimistic. The company's strategic focus on membership growth and value-based contracts supports a positive outlook, likely leading to a 2%-8% stock price increase over the next two weeks.
Astrana's earnings call highlights strong financial performance with record revenue growth and optimistic future guidance. The acquisition strategy and partnership announcements, such as with Provider Health Link, indicate potential for significant revenue increases. Despite some risks, including integration challenges and debt management, the company's strategic moves and guidance suggest positive market sentiment. The absence of a share repurchase program is a minor drawback. Overall, the positive aspects outweigh the negatives, leading to a positive stock price prediction over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
